CG Oncology director executes 10b5-1 sale after option exercise, reports zero holdings
Rhea-AI Filing Summary
James J. Mulay, a director of CG Oncology, Inc. (CGON), exercised a fully vested director stock option to buy 27,015 shares at an exercise price of $0.60 on 09/05/2025. The same day he sold a total of 27,015 common shares under a Rule 10b5-1 trading plan adopted June 6, 2025, at weighted-average prices ranging across four blocks: $30.47, $31.42, $32.64, and $33.22. Following these transactions the reporting person reports 0 shares beneficially owned. Sales were effected pursuant to the 10b5-1 plan and the option was fully vested.
Positive
- Trades executed under a Rule 10b5-1 plan, indicating pre-established, documented trading instructions
- Option exercise was fully vested, showing the director had the right to exercise at the reported time
- Weighted-average sale prices disclosed and the filer offers to provide detailed per-trade pricing on request
Negative
- Reporting person holds 0 shares following these transactions, showing a complete disposition of direct holdings
- Significant insider sales of 27,015 shares occurred on a single day, which may be interpreted as insider liquidity
Insights
TL;DR Insider exercised low-cost options and sold all resulting shares the same day under a 10b5-1 plan; reporting shows no remaining ownership.
The filing shows a director exercised 27,015 options at $0.60 and sold the resulting shares on 09/05/2025 under a Rule 10b5-1 plan adopted on June 6, 2025. Sales occurred in multiple transactions at weighted-average prices reported in four tranches between $30.47 and $33.22. The rapid exercise-and-sale sequence realized a substantial per-share spread relative to the exercise price and left the director with 0 shares reported post-transaction. These are factual, structured insider liquidity events rather than disclosed changes to company operations or guidance.
TL;DR Transactions were executed under a documented 10b5-1 plan; reporting meets Section 16 disclosure requirements and shows full disposition.
The Form 4 discloses that the sales were effected pursuant to a pre-established Rule 10b5-1 trading plan, which provides affirmative defense protection for predetermined trades. The option shown was fully vested and the Form 4 reports the director retained no direct beneficial ownership after the reported trades. The filing includes weighted-average sale prices and offers to provide further breakdowns on specific execution prices upon request, which supports transparency in pricing disclosure.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Director Stock Option (right to buy) | 27,015 | $0.00 | -- |
| Exercise | Common Stock | 27,015 | $0.60 | $16K |
| Sale | Common Stock | 12,342 | $30.47 | $376K |
| Sale | Common Stock | 4,095 | $31.42 | $129K |
| Sale | Common Stock | 7,465 | $32.64 | $244K |
| Sale | Common Stock | 3,113 | $33.22 | $103K |
Footnotes (1)
- The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.01 to $31.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.06 to $33.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.06 to $33.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Fully vested
AI-generated analysis. How Rhea-AI works. Not financial advice.
